Loading...
Docoh

Enzo Biochem (ENZ)

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Company profile

Ticker
ENZ
Exchange
Website
CEO
Elazar Rabbani
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Enzo Clinical Labs, Inc. • Enzo Life Sciences, Inc. • Enzo Therapeutics, Inc. • Enzo Realty LLC • Enzo Realty II, LLC ...
IRS number
132866202

ENZ stock data

Calendar

9 Jun 22
16 Aug 22
31 Jul 23
Quarter (USD) Apr 22 Jan 22 Oct 21 Jul 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jul 21 Jul 20 Jul 19 Jul 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 32.13M 32.13M 32.13M 32.13M 32.13M 32.13M
Cash burn (monthly) (no burn) (no burn) 1.62M 1.12M 282.33K 617.67K
Cash used (since last report) n/a n/a 5.78M 3.99M 1.01M 2.21M
Cash remaining n/a n/a 26.35M 28.14M 31.12M 29.92M
Runway (months of cash) n/a n/a 16.3 25.2 110.2 48.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jul 22 Kara Cannon Common Stock, $0.01 Par Value Buy Acquire P No No 2.42 2,500 6.05K 2,500
12 Jul 22 Radoff Bradley Louis Common Stock, $0.01 Par Value Buy Acquire P No No 2.27 12,500 28.38K 4,194,663
12 Jul 22 Radoff Bradley Louis Common Stock, $0.01 Par Value Grant Acquire A No No 0 41,666 0 4,236,329
12 Jul 22 Mary Tagliaferri Common Stock, $0.01 Par Value Grant Acquire A No No 0 41,666 0 80,729
12 Jul 22 Ian B. Walters Common Stock, $0.01 Par Value Grant Acquire A No No 0 41,666 0 80,729
37.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 50 61 -18.0%
Opened positions 3 11 -72.7%
Closed positions 14 15 -6.7%
Increased positions 12 9 +33.3%
Reduced positions 13 17 -23.5%
13F shares Current Prev Q Change
Total value 65.1M 88.23M -26.2%
Total shares 21.72M 27.07M -19.8%
Total puts 30.1K 49.4K -39.1%
Total calls 55.7K 44.1K +26.3%
Total put/call ratio 0.5 1.1 -51.8%
Largest owners Shares Value Change
Harbert Discovery Fund 5.18M $17.03M 0.0%
Renaissance Technologies 3.01M $8.73M -2.7%
Roumell Asset Management 2.39M $6.94M -1.8%
Vanguard 1.77M $5.14M -0.7%
Dimensional Fund Advisors 1.59M $4.62M -0.1%
BLK Blackrock 1.54M $4.47M +0.5%
VIEX Capital Advisors 1.44M $4.16M -17.3%
Fuller & Thaler Asset Management 951.24K $2.76M +0.5%
Boothbay Fund Management 539.95K $1.57M +69.0%
Potomac Capital Management 496.81K $1.44M +138.8%
Largest transactions Shares Bought/sold Change
Harbert Fund Advisors 0 -5.18M EXIT
AMH Equity 30K -566.74K -95.0%
MS Morgan Stanley 488.18K +469.27K +2482.5%
VIEX Capital Advisors 1.44M -300.96K -17.3%
Potomac Capital Management 496.81K +288.81K +138.8%
Boothbay Fund Management 539.95K +220.45K +69.0%
Renaissance Technologies 3.01M -83.6K -2.7%
Bridgeway Capital Management 375.4K +64.2K +20.6%
SNS Financial 62.5K +62.5K NEW
IVZ Invesco 0 -59.24K EXIT

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: consumed, cumulative, home, HRSA, independent, prevalence, requisition, responded, RSU, stipulation, volatility, Walter
Removed: automatic, automatically, began, begin, Charter, delayed, extended, falsely, letter, ongoing, opposition, planned, Proposed, repayment, reply, scheduled, significance, stated, submit, Supermajority, unrealized, Vote

Patents

Utility
Assays for Detecting Modified Compounds
3 Feb 22
Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified.
Utility
Pharmaceutical Compositions and Methods Targeting WNT Pathway Proteins
27 Jan 22
Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213.
Utility
Immunomodulatory Pharmaceutical Compositions Including a Synthetic Peptide and Transforming Growth Factor Beta
27 Jan 22
The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Utility
Fluorescence Quencher Polymer Conjugates and Uses Thereof
27 Jan 22
The invention provides chemical conjugates comprising a plurality of fluorescence quenching moieties conjugated to polymer and the use of such conjugates to quench the emission of fluorescence from emitters including macromolecular fluorescent emitters such as phycoerythrin.
Utility
Assays for detecting modified compounds
23 Nov 21
Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified.